BranchLab raises $26M to bring AI to pharma commercialisation

What's the deal? BranchLab, a startup building an AI platform for pharmaceutical commercialisation, has raised $26M in a Series A round led by McKesson Ventures. The company's technology helps pharma companies improve marketing efficacy — by as much as 70%, according to the company.

Why now? Pharmaceutical companies are under growing pressure to justify their marketing spend and demonstrate measurable returns. AI tools that can optimise commercial strategies and target the right healthcare providers are becoming essential as drug launches grow more competitive and costly.

McKesson, one of the largest healthcare distribution companies in the world, leading the round through its venture arm signals strategic interest — not just financial. The investment gives BranchLab access to McKesson's vast healthcare data ecosystem and distribution network.

What could go wrong? Healthcare is one of the most heavily regulated industries, and any AI platform handling pharma marketing must navigate strict compliance rules around drug promotion. Scaling an AI tool in this environment means clearing regulatory hurdles that don't exist in other sectors.

There's also the question of whether a 70% improvement in marketing efficacy can hold up across different drug categories and markets, or whether it reflects early results from a narrow set of use cases.

The signal: This deal reflects a broader trend of AI penetrating the commercial side of pharma — not just drug discovery and clinical trials, where most attention has focused. As pharma companies look beyond R&D for efficiency gains, startups that can prove ROI on marketing and sales operations are attracting serious capital and strategic backing.

Read more: prnewswire.com